ct125a cells
Cell therapyexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 31, 2021 (NCT04767308)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- T-cell surface glycoprotein CD5Immunity, passive
immunity, passive - CD5
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05487495 | Phase 1 | Jul 27, 2022 | Beijing Boren Hospital |
| NCT04767308 | Early Phase 1 (Phase 1) | Mar 31, 2021 | Huazhong University of Science and Technology, IASO Pharma Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Beijing Boren Hospital | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 1 | 1 | 2021 |
| IASO Pharma Inc. | For profit | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1